TCGA-G2-A2EC-01A-11R-A180-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 22.86465177
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- UV_RESPONSE_DN+0.370
- APICAL_SURFACE+0.310
- HEDGEHOG_SIGNALING+0.310
- KRAS_SIGNALING_UP+0.290
- ALLOGRAFT_REJECTION+0.280
- APICAL_JUNCTION+0.280
- BILE_ACID_METABOLISM+0.280
- COAGULATION+0.270
Top 10 suppressed
- E2F_TARGETS-0.710
- MYC_TARGETS_V2-0.710
- G2M_CHECKPOINT-0.630
- MYC_TARGETS_V1-0.620
- OXIDATIVE_PHOSPHORYLATION-0.510
- DNA_REPAIR-0.500
- MTORC1_SIGNALING-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.470
- MITOTIC_SPINDLE-0.400
- INTERFERON_ALPHA_RESPONSE-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-03268 | — | cohortA1 | 0.906 |
| 2 | TCGA-CR-6488-01A-12R-2081-07 | — | — | 0.898 |
| 3 | SRR8613742 | — | A | 0.895 |
| 4 | TCGA-86-8668-01A-11R-2403-07 | — | cohortA1 | 0.886 |
| 5 | SRR15069598 | — | — | 0.885 |
| 6 | TCGA-55-8096-01A-11R-2241-07 | — | cohortA1 | 0.884 |
| 7 | TCGA-AC-A2FF-01A-11R-A17B-07 | — | A | 0.883 |
| 8 | TCGA-SY-A9G0-01A-12R-A38B-07 | — | — | 0.879 |
| 9 | TCGA-AC-A8OS-01A-12R-A41B-07 | — | A | 0.878 |
| 10 | TCGA-BB-8596-01A-11R-2403-07 | — | — | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |